JP2025508122A5 - - Google Patents

Info

Publication number
JP2025508122A5
JP2025508122A5 JP2024553758A JP2024553758A JP2025508122A5 JP 2025508122 A5 JP2025508122 A5 JP 2025508122A5 JP 2024553758 A JP2024553758 A JP 2024553758A JP 2024553758 A JP2024553758 A JP 2024553758A JP 2025508122 A5 JP2025508122 A5 JP 2025508122A5
Authority
JP
Japan
Prior art keywords
methyl
optionally substituted
piperazine
methylcarbamoyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/077988 external-priority patent/WO2023169226A1/en
Publication of JP2025508122A publication Critical patent/JP2025508122A/ja
Publication of JP2025508122A5 publication Critical patent/JP2025508122A5/ja
Pending legal-status Critical Current

Links

JP2024553758A 2022-03-11 2023-02-23 Parp阻害剤としての置換三環式化合物およびその使用 Pending JP2025508122A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202210260944 2022-03-11
CN202210260944.7 2022-03-11
CN202210448803 2022-04-24
CN202210448803.8 2022-04-24
CN202211219599 2022-09-30
CN202211219599.9 2022-09-30
CN202211505904.0 2022-11-28
CN202211505904 2022-11-28
PCT/CN2023/077988 WO2023169226A1 (en) 2022-03-11 2023-02-23 Substituted tricyclic compounds as parp inhibitors and the use thereof

Publications (2)

Publication Number Publication Date
JP2025508122A JP2025508122A (ja) 2025-03-21
JP2025508122A5 true JP2025508122A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=87937164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553758A Pending JP2025508122A (ja) 2022-03-11 2023-02-23 Parp阻害剤としての置換三環式化合物およびその使用

Country Status (11)

Country Link
US (1) US20250215013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490161A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508122A (cg-RX-API-DMAC7.html)
KR (1) KR20240162104A (cg-RX-API-DMAC7.html)
CN (1) CN119013279A (cg-RX-API-DMAC7.html)
AU (1) AU2023229992A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253468A1 (cg-RX-API-DMAC7.html)
IL (1) IL315586A (cg-RX-API-DMAC7.html)
MX (1) MX2024011086A (cg-RX-API-DMAC7.html)
TW (1) TW202400601A (cg-RX-API-DMAC7.html)
WO (1) WO2023169226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
JP2026507185A (ja) * 2023-03-01 2026-02-27 インパクト セラピューティクス (シャンハイ), インコーポレイテッド Parp阻害剤としての置換窒素含有三環式化合物及びその使用
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作parp1抑制劑的化合物、其用途及包含其之組合物
WO2026142998A1 (en) * 2024-12-24 2026-07-02 Gilead Sciences, Inc. Crystalline forms of a parp1 inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
MX2009007053A (es) * 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023122140A1 (en) * 2021-12-22 2023-06-29 Synnovation Therapeutics, Inc. Parp1 inhibitors
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
PT4497438T (pt) * 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof

Similar Documents

Publication Publication Date Title
JP7634606B2 (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
JP7129420B2 (ja) Hpk1阻害剤としてのイソキノリン
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2024532735A (ja) 複素環式化合物及び使用方法
WO2024229442A1 (en) Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer
CA3213079A1 (en) Amino-substituted heterocycles for treating cancers with egfr mutations
EP3846800A1 (en) Compounds for the degradation of brd9 or mth1
WO2019183364A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
JP7628089B2 (ja) 三環式化合物およびそれらの用途
KR102659211B1 (ko) G1t38의 형체 형태 및 그의 제조 방법
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
TW201618773A (zh) Btk抑制劑、pi3k抑制劑、jak-2抑制劑、及/或cdk4/6抑制劑的治療組合物
TW201618772A (zh) Btk抑制劑、pi3k抑制劑、jak-2抑制劑及/或bcl-2抑制劑之治療組合物
CA2963736A1 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
KR20200108867A (ko) G1t38 우수한 투여 요법
WO2016040848A1 (en) Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2018005863A1 (en) Pyrimidine-based compounds for the treatment of cancer
JP2025508122A (ja) Parp阻害剤としての置換三環式化合物およびその使用
JP6847954B2 (ja) キナーゼ阻害剤としての三環式化合物および組成物
EP4025570A1 (en) Hydantoin derivative
JP2024513538A5 (cg-RX-API-DMAC7.html)
AU2013318283A1 (en) Dihydropyrrolidino-pyrimidines as kinase inhibitors
CN116940573A (zh) 三环类化合物及其用途
RU2024127255A (ru) Замещенные трициклические соединения в качестве ингибиторов parp и их применение
RU2024107785A (ru) Замещенные трициклические соединения в качестве ингибиторов parp и их применение